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ABSTRACT 
 
Primary immunodeficiency diseases (PIDs) are composed by a group of highly 
heterogeneous immune system diseases, of which approximately 350 forms of PID have been 
described so far. The causative gene of around 60% of patients with PIDs has yet unknown. 
In recent years, Next Generation Sequencing (NGS) has been increasingly adopted for gene 
identification and molecular diagnosis of rare diseases, including PIDs. An overview of the 
genetic makeup that underlies PID using NGS has been suggested as a promising approach 
to elucidate the etiology of PIDs, which could yield diagnostic and, possibly, provide new 
treatment advances for PID. 
 
To approach this goal, we performed either whole exome sequencing (WES, 454 samples) 
or targeted region sequencing (TRS, 217 samples) on 602 samples of 500 PID pedigrees. We 
have summarized the practical suggestions for the interpretation of NGS data and the 
techniques that can be used to search disease-causative PID genes in Paper I. This work aims 
to improve data annotation, interpretation, and application of NGS data in PIDs, which also 
facilitates a wide range of application of NGS data analysis in other Mendelian disorders. 
 
The genetic approach together with immunological investigations have identified potential 
pathogenic variants in 86 primary antibody deficiency (PAD) patients (68.2%), and a correct 
diagnosis can guide/change treatment plan in around half of the patients with PAD (Paper 
II). We identified potentially disease-causing variants (including variants classified as VUS 
(variants of unknown clinical significance)) in around 34% of genetically unidentified PID 
samples, which had been subjected to TRS using a panel of 219 common PID genes. Notably, 
the genetic diagnosis of a specific atypical ITK deficiency case adds to the growing amount 
of evidence supporting the importance of genetic investigations initiated at an early stage of 
the patient´s disease (Paper III).  
 
Altogether, around 60% of PID patients have a possible diagnosis via WES/TRS. Copy 
number variation defects were identified in 16 patients (4 genes were involved, LRBA, ATM, 
DOCK8 and PMS2). Beyond the identification of the monogenic causal gene based on 
pedigree analysis, mutation frequency analysis has been used to identify genes with rare 
functional variants in the higher proportion of patients in specific patient group compared to 
control samples, which have discovered several potential novel PID genes (TNFRSF18, 
PIK3CG, LILRB1, EPHB2, TXNIP, CD5 and NLRP5). Other possible models beyond the 
monogenic scenario were also explored, and 16 severe combined immunodeficiency (SCID) 
or common variable immunodeficiency (CVID) patients might be due to an accumulation of 
rare amino acid substitution variants in genes related to the same function or pathway (RAG1 
& RAG2, RAG1 & ATM, C3 & ITGB2, PRKDC & ATM, C5 & NIPBL, LRBA & CR2, CR2 
& NFKB1, UNC93B1 & NIPBL, PLCG2 & NOD2 and IGLL1 & ATM). These findings 
indicate that NGS, together with a large sample size, is powerful in decoding the genetic 
characteristics of PID and provide insight into molecular mechanisms that cause the disease. 
 
Existing variants impact prediction software/algorithms still have a challenge to evaluate the 
pathological consequences of the prioritized variants or genes. We thus developed a Random 
  
Forest-based discriminator, Variant Impact Predictor for PIDs (VIPPID), to refine the 
prediction algorithms, which utilized the features of pathogenic variants and benign 
mutations, integrated with other 24 predictive softwares currently used. Evaluation of 
VIPPID showed that it had superior performance (AUC=0.95) over existing tools, we also 
showed the gene-specific model outperformed the non-gene-specific model and provided a 
possibility to explore the underlying molecular mechanism based on our gene-specific model 
in Paper IV. 
 
Specific mutations of PID causative genes may exert different effects on TCR repertoire 
diversity and composition, which ultimately lead to heterogeneous phenotypes. DNA damage 
response/methylation is an essential process during antigen receptor recombination. To 
investigate the effect of mutations in DNA repair genes on adaptive immunity, 19 patients 
with DNA repair/methylation defects were selected and subdivided into several groups based 
on their causative genes, we then performed deep immune repertoire sequencing and 
comparison with 14 age-matched healthy controls.  
 
Patients with different molecular diagnosis exhibited distinct repertoire diversity, clonality 
and V-J pairing patterns. Aberrant complementarity-determining region 3 (CDR3) length 
distribution was observed both in unproductive and productive TCRs in all patients, 
suggesting that it predominantly arose before thymic selection. Shorter CDR3 lengths in AT 
patients resulted from a decreased number of insertions, led to an increase in the number of 
shared clonotypes, whereas patients with DNMT3B and ZBTB24 mutations presented longer 
CDR3 lengths and reduced specificity for pathogen-associated CDR3 sequences (Paper V). 
This study revealed the role of DNA repair/methylation machinery in patients with ATM, 
DNMT3B and ZBTB24 deficiency, and shed light on the mechanistic etiology of their T cell 
dysfunction.  
 
  
LIST OF SCIENTIFIC PAPERS 
I. M. Fang, H. Abolhassani, C. K. Lim, J. Zhang, L. Hammarstrom, Next 
Generation Sequencing Data Analysis in Primary Immunodeficiency 
Disorders - Future Directions. Journal of clinical immunology 36 Suppl 1, 68-
75 (2016).  
 
 
II. H. Abolhassani, A. Aghamohammadi, M. Fang, N. Rezaei, C. Jiang, X. Liu, 
Q. Pan-Hammarstrom, L. Hammarstrom, Clinical implications of systematic 
phenotyping and exome sequencing in patients with primary antibody 
deficiency. Genetics in medicine 21, 243-251 (2019). 
 
 
III. M. Fang, H. Abolhassani, Q. Pan-Hammarstrom, E. Sandholm, X. Liu, L. 
Hammarstrom, Compound Heterozygous Mutations of IL2-Inducible T cell 
Kinase in a Swedish Patient: the Importance of Early Genetic Diagnosis. 
Journal of clinical immunology 39, 131-134 (2019). 
IV. M. Fang, H. Abolhassani, Z. Su, Y. Itan, L. Hammarström. VIPPID: a gene 
specific single nucleotide variant pathogenicity prediction tool for Primary 
Immunodeficiency Diseases. Preliminary Manuscript. 
V. M. Fang, Z. Su, H. Abolhassani, W. Zhang, C. Jiang, B. Cheng, L. Lin, X. 
Wang, S. Wang, L. Wang, L. Luo, A. Aghamohammadi, T. Li, J. Wu, X. 
Zhang, L. Hammarström, X. Liu. Abnormality in the T cell repertoire 
contributes to immunodeficiency in patients with DNA repair/methylation 
defects. Manuscript. 
 
 
  
  
 
PUBLICATIONS NOT INCLUDED IN THE THESIS (2015-
2019) 
(* Equal contributions) 
 
1. C. Jespersgaard*, M. Fang*, M. Bertelsen, X. Dang, H. Jensen, Y. Chen, N. Bech, L. 
Dai, T. Rosenberg, J. Zhang, L. B. Moller, Z. Tumer, K. Brondum-Nielsen, K. 
Gronskov, Molecular genetic analysis using targeted NGS analysis of 677 individuals 
with retinal dystrophy. Scientific reports 9, 1219 (2019). 
 
2. S. Bigoni, M. Neri, C. Scotton, R. Farina, P. Sabatelli, C. Jiang, J. Zhang, M. S. 
Falzarano, R. Rossi, D. Ognibene, R. Selvatici, F. Gualandi, D. Bosshardt, P. Perri, C. 
Campa, F. Brancati, M. Salvatore, M. C. De Stefano, D. Taruscio, L. Trombelli, M. 
Fang, A. Ferlini, Homozygous recessive versican missense variation is associated with 
early teeth loss in a Pakistani family. Frontiers in genetics 9, 723 (2018). 
 
3. V. Yahalom, N. Pillar, Y. Zhao, S. Modan, M. Fang, L. Yosephi, O. Asher, E. Shinar, 
G. Celniker, H. Resnik-Wolf, Y. Brantz, H. Hauschner, N. Rosenberg, L. Cheng, N. 
Shomron, E. Pras, SMYD1 is the underlying gene for the AnWj negative blood group 
phenotype. European journal of haematology 101, 496-501 (2018). 
 
4. N. Pillar*, O. Pleniceanu*, M. Fang*, L. Ziv, E. Lahav, S. Botchan, L. Cheng, B. 
Dekel, N. Shomron, A rare variant in the FHL1 gene associated with X-linked recessive 
hypoparathyroidism. Human genetics 136, 835-845 (2017). 
 
5. F. Gualandi, F. Zaraket, M. Malagu, G. Parmeggiani, C. Trabanelli, S. Fini, X. Dang, 
X. Wei, M. Fang, M. Bertini, R. Ferrari, A. Ferlini, Mutation load of multiple ion 
channel gene mutations in Brugada Syndrome. Cardiology 137, 256-260 (2017). 
 
6. H. Abolhassani, E. S. Edwards, A. Ikinciogullari, H. Jing, S. Borte, M. Buggert, L. Du, 
M. Matsuda-Lennikov, R. Romano, R. Caridha, S. Bade, Y. Zhang, J. Frederiksen, M. 
Fang, S. K. Bal, S. Haskologlu, F. Dogu, N. Tacyildiz, H. F. Matthews, J. J. McElwee, 
E. Gostick, D. A. Price, U. Palendira, A. Aghamohammadi, B. Boisson, N. Rezaei, A. 
C. Karlsson, M. J. Lenardo, J. L. Casanova, L. Hammarstrom, S. G. Tangye, H. C. Su, 
Q. Pan-Hammarstrom, Combined immunodeficiency and Epstein-Barr virus-induced 
B cell malignancy in humans with inherited CD70 deficiency. The Journal of 
experimental medicine 214, 91-106 (2017). 
 
7. R. F. Schindler, C. Scotton, J. Zhang, C. Passarelli, B. Ortiz-Bonnin, S. Simrick, T. 
Schwerte, K. L. Poon, M. Fang, S. Rinne, A. Froese, V. O. Nikolaev, C. Grunert, T. 
Muller, G. Tasca, P. Sarathchandra, F. Drago, B. Dallapiccola, C. Rapezzi, E. 
Arbustini, F. R. Di Raimo, M. Neri, R. Selvatici, F. Gualandi, F. Fattori, A. Pietrangelo, 
W. Li, H. Jiang, X. Xu, E. Bertini, N. Decher, J. Wang, T. Brand, A. Ferlini, 
POPDC1(S201F) causes muscular dystrophy and arrhythmia by affecting protein 
trafficking. The Journal of clinical investigation 126, 239-253 (2016). 
 
8. S. Olgiati*, M. Quadri*, M. Fang*, J. P. Rood, J. A. Saute, H. F. Chien, C. G. 
Bouwkamp, J. Graafland, M. Minneboo, G. J. Breedveld, J. Zhang, F. W. Verheijen, 
A. J. Boon, A. J. Kievit, L. B. Jardim, W. Mandemakers, E. R. Barbosa, C. R. Rieder, 
K. L. Leenders, J. Wang, V. Bonifati, DNAJC6 mutations associated with early-onset 
Parkinson's disease. Annals of neurology 79, 244-256 (2016). 
 
9. I. Masuho*, M. Fang*, C. Geng, J. Zhang, H. Jiang, R. K. Ozgul, D. Y. Yilmaz, D. 
Yalnizoglu, D. Yuksel, A. Yarrow, A. Myers, S. C. Burn, P. L. Crotwell, S. Padilla-
Lopez, A. Dursun, K. A. Martemyanov, M. C. Kruer, Homozygous GNAL mutation 
associated with familial childhood-onset generalized dystonia. Neurology. Genetics 2, 
e78 (2016). 
 
10. E. Gregianin, G. Pallafacchina, S. Zanin, V. Crippa, P. Rusmini, A. Poletti, M. Fang, 
Z. Li, L. Diano, A. Petrucci, L. Lispi, T. Cavallaro, G. M. Fabrizi, M. Muglia, F. 
Boaretto, A. Vettori, R. Rizzuto, M. L. Mostacciuolo, G. Vazza, Loss-of-function 
mutations in the SIGMAR1 gene cause distal hereditary motor neuropathy by impairing 
ER-mitochondria tethering and Ca2+ signalling. Human molecular genetics 25, 3741-
3753 (2016). 
 
11. L. Gao, X. Dang, L. Huang, L. Zhu, M. Fang, J. Zhang, X. Xu, L. Zhu, T. Li, L. Zhao, 
J. Wei, J. Zhou, Search for the potential "second-hit" mechanism underlying the onset 
of familial hemophagocytic lymphohistiocytosis type 2 by whole-exome sequencing 
analysis. Translational research 170, 26-39 (2016). 
 
12. C. Dallabona, T. E. Abbink, R. Carrozzo, A. Torraco, A. Legati, C. G. van Berkel, M. 
Niceta, T. Langella, D. Verrigni, T. Rizza, D. Diodato, F. Piemonte, E. Lamantea, M. 
Fang, J. Zhang, D. Martinelli, E. Bevivino, C. Dionisi-Vici, A. Vanderver, S. G. Philip, 
M. A. Kurian, I. C. Verma, S. Bijarnia-Mahay, S. Jacinto, F. Furtado, P. Accorsi, A. 
Ardissone, I. Moroni, I. Ferrero, M. Tartaglia, P. Goffrini, D. Ghezzi, M. S. van der 
Knaap, E. Bertini, LYRM7 mutations cause a multifocal cavitating 
leukoencephalopathy with distinct MRI appearance. Brain 139, 782-794 (2016). 
 
13. O. K. Alkhairy, H. Abolhassani, N. Rezaei, M. Fang, K. K. Andersen, Z. 
Chavoshzadeh, I. Mohammadzadeh, M. A. El-Rajab, M. Massaad, J. Chou, A. 
Aghamohammadi, R. S. Geha, L. Hammarstrom, Spectrum of phenotypes associated 
with mutations in LRBA. Journal of clinical immunology 36, 33-45 (2016). 
 
14. A. Reyes, L. Melchionda, A. Nasca, F. Carrara, E. Lamantea, A. Zanolini, C. Lamperti, 
M. Fang, J. Zhang, D. Ronchi, S. Bonato, G. Fagiolari, M. Moggio, D. Ghezzi, M. 
Zeviani, RNASEH1 mutations impair mtDNA replication and cause Adult-Onset 
Mitochondrial Encephalomyopathy. American journal of human genetics 97, 186-193 
(2015). 
 
  
15. A. E. Pen, M. Nyegaard, M. Fang, H. Jiang, R. Christensen, H. Molgaard, H. Andersen, 
B. P. Ulhoi, J. R. Ostergaard, S. Vaeth, M. Sommerlund, A. P. de Brouwer, X. Zhang, 
U. B. Jensen, A novel single nucleotide splice site mutation in FHL1 confirms an 
Emery-Dreifuss plus phenotype with pulmonary artery hypoplasia and facial 
dysmorphology. European journal of medical genetics 58, 222-229 (2015). 
 
16. A. Masotti, P. Uva, L. Davis-Keppen, L. Basel-Vanagaite, L. Cohen, E. Pisaneschi, A. 
Celluzzi, P. Bencivenga, M. Fang, M. Tian, X. Xu, M. Cappa, B. Dallapiccola, 
Keppen-Lubinsky syndrome is caused by mutations in the inwardly rectifying K+ 
channel encoded by KCNJ6. American journal of human genetics 96, 295-300 (2015). 
 
17. O. K. Alkhairy, R. Perez-Becker, G. J. Driessen, H. Abolhassani, J. van Montfrans, S. 
Borte, S. Choo, N. Wang, K. Tesselaar, M. Fang, K. Bienemann, K. Boztug, A. 
Daneva, F. Mechinaud, T. Wiesel, C. Becker, G. Duckers, K. Siepermann, M. C. van 
Zelm, N. Rezaei, M. van der Burg, A. Aghamohammadi, M. G. Seidel, T. Niehues, L. 
Hammarstrom, Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and 
genetic characterization of human CD27 deficiency. The Journal of allergy and clinical 
immunology 136, 703-712.e710 (2015). 
 
18. M. Robusto, M. Fang*, R. Asselta, P. Castorina, S. C. Previtali, S. Caccia, E. Benzoni, 
R. De Cristofaro, C. Yu, A. Cesarani, X. Liu, W. Li, P. Primignani, U. Ambrosetti, X. 
Xu, S. Duga, G. Solda, The expanding spectrum of PRPS1-associated phenotypes: 
three novel mutations segregating with X-linked hearing loss and mild peripheral 
neuropathy. European journal of human genetics 23, 766-773 (2015) 
  
CONTENTS 
1 INTRODUCTION ............................................................................................... 1 
1.1 Primary Immunodeficiency ......................................................................... 1 
1.2 Next Generation Sequencing Technology .................................................. 1 
1.3 Bioinformatic Analysis ............................................................................... 3 
1.3.1 Candidate gene prioritization .......................................................... 4 
1.3.2 CNV detection ................................................................................. 5 
1.4 Variant Interpretation and Classification .................................................... 6 
1.5 Oligogenic Analysis .................................................................................... 6 
1.6 Validation and Replication .......................................................................... 7 
1.7 Multiomics Approaches .............................................................................. 7 
1.7.1 Epigenetics ...................................................................................... 8 
1.7.2 Transcriptomics ............................................................................... 8 
1.7.3 Proteomics ....................................................................................... 8 
1.7.4 Metagenomics ................................................................................. 9 
1.7.5 Immune repertoires ......................................................................... 9 
1.7.6 Pathogen detection ........................................................................ 10 
2 AIMS .................................................................................................................. 11 
2.1 General Aim .............................................................................................. 11 
2.2 Specific Aims ............................................................................................ 11 
3 MATERIALS AND METHODS ...................................................................... 13 
3.1 Subjects ...................................................................................................... 13 
3.2 Genomics Data Generation and Preprocessing ......................................... 13 
3.2.1 Whole exome sequencing (WES) ................................................. 13 
3.2.2 Targeted region sequencing (TRS) ............................................... 13 
3.2.3 Sequence alignment, variants calling and annotation ................... 13 
3.2.4 Candidate prioritization ................................................................. 13 
3.2.5 Data mining ................................................................................... 14 
3.2.6 Validation and replication ............................................................. 15 
3.3 Predicting Pathogenicity of Single Nucleotide Variations for Primary 
Immunodeficiency Diseases ..................................................................... 15 
3.3.1 Selection of training dataset for the prediction model .................. 15 
3.3.2 Annotation of the mutations .......................................................... 15 
3.3.3 Machine learning and calculation of feature importance ............. 15 
3.4 Immune Repertoire .................................................................................... 16 
3.4.1 Sequencing of TCRb repertoires .................................................. 16 
3.4.2 Bioinformatics analyses of TCRb repertoires .............................. 16 
3.4.3 Analysis of pathogen-associated sequences ................................. 17 
3.4.4 Statistical analysis of immune repertoire ...................................... 17 
3.5 Ethical Considerations ............................................................................... 17 
3.5.1 Risk assessment ............................................................................. 17 
  
3.5.2 Potential benefits ........................................................................... 18 
4 RESULTS AND DISCUSSION ........................................................................ 19 
4.1 Cohort Spectrum ........................................................................................ 19 
4.2 Nonpathogenic Genetic Variants .............................................................. 19 
4.3 Molecular Diagnosis ................................................................................. 20 
4.3.1 Pedigree analysis ........................................................................... 20 
4.3.2 Mutation frequency analysis ......................................................... 21 
4.3.3 Digenic analysis ............................................................................ 22 
4.3.4 The importance of early molecular diagnosis ............................... 22 
4.4 Random Forest-based Variant Impact Predictor ....................................... 23 
4.5 Immune Repertoire .................................................................................... 24 
4.5.1 Restriction of TCR correlates with the pathogenic cause and the 
clinical phenotype ......................................................................... 24 
4.5.2 Discrepant enrichment of pathology associated T cells contributes 
to the phenotypic heterogeneity of immunodeficiencies .............. 25 
5 CONCLUSION AND FUTURE PERSPECTIVES ......................................... 27 
6 ACKNOWLEDGMENTS ................................................................................. 29 
7 REFERENCES ................................................................................................... 31 
 
 
  
LIST OF ABBREVIATIONS 
ACMG  American College of Medical Genetics and Genomics 
AD  Autosomal Dominant 
AID  Autoimmune disease 
AR  Autosomal Recessive 
AT  Ataxia-Telangiectasia 
ATM  Ataxia-telangiectasia mutated kinase 
AUC   Area under the curve 
BCR  B cell receptors 
BLAST  Basic Local Alignment Search Tool 
BWA  Burrows-Wheeler Aligner 
CADD  Combined Annotation-Dependent Depletion 
CD  Coverage depth 
CDR3  Complementarity-determining region 3 
ChIP   Chromatin immunoprecipitation 
CID  Combined Immunodeficiency 
CNV  Copy number variation 
CVID  Common variable immunodeficiency 
DDR  DNA-damage response  
DSBs  DNA double-strand breaks 
EBV  Epstein-Barr virus 
ELISA  Multiplex enzyme-linked immunosorbent assay 
EMSA   Electrophoretic mobility shift assay 
ENCODE   The Encyclopedia of DNA Elements Project 
ESID  European Society for Immunodeficiencies 
ESP  Exome Variant Server 
ExAC  Exome Aggregation Consortium 
FDR  False discovery rate 
GATK  Genome Analysis Toolkit  
GC  Guanine-Cytosine 
GDI  Gene damage index 
GTEx   Genotype-Tissue Expression Project 
gnomAD  The Genome Aggregation Database 
GOF  Gain-of-function 
GQ  Genotyping quality 
GWAS  Genome-wide association study 
HGMD  Human Gene Mutation Database 
HLH  Hemophagocytic Lymphohistiocytosis 
HR  Homologous recombination  
ICF  The Immunodeficiency, Centromeric instability, and Facial anomalies  
IgA  Immunoglobulin A 
IgG  Immunoglobulin G 
IgM  Immunoglobulin M 
InDels  Insertion/deletion 
KG  The 1000 Genomes Project 
KRECs  κ-deleting recombination excision circles 
LOF  Loss-of-function 
mRNA  Messenger RNA 
MSC  Mutation Significance Cutoff 
ncRNA Non-coding RNA 
NGS Next-generation sequencing 
NHEJ Non-homologous DNA end joining 
nsSNVs Non-synonymous single nucleotide variation 
PAD Primary antibody deficiency 
paTCR Pathology-associated TCR 
PCA Principal components analysis 
PCR Polymerase chain reaction 
PID Primary immunodeficiency 
PolyPhen2 Polymorphism Phenotyping v2 
PTM Post-translational modification 
RAPID The Resource of Asian Primary Immunodeficiency Diseases database 
ROC Receiver Operating Characteristics 
RSSs The recombination signal sequences  
RT-PCR Real-time polymerase chain reaction 
SCID Severe combined immunodeficiency 
SIFT Sorting intolerant from tolerant 
SNP Single nucleotide polymorphism 
SnpEff Single nucleotide polymorphism effect 
SNV Single-nucleotide variant 
SOAP Short oligonucleotide alignment program 
stLFR Single tube long fragment read 
TCR T cell receptors 
TdT Terminal deoxynucleotidyl transferase 
TRECs T-cell receptor excision circles
TRS Targeted region sequencing
UTR Untranslated Regions
VEP Variant Effect Predictor
VIPPID Variant Impact Predictor for Primary immunodeficiency
VUS Variants of unknown significance
WES Whole exome sequencing
WGS Whole genome sequencing
XR X-linked recessive
  1 
1 INTRODUCTION 
1.1 PRIMARY IMMUNODEFICIENCY 
Primary immunodeficiency diseases (PIDs) consist of a class of immune deficient diseases with 
high heterogeneity, predisposing individuals to an increased frequency and severity of 
infections, immune dysregulation, autoimmune manifestations and malignancy (1). The 
incidence of PID varies in different populations and there are an expected 6 million affected 
individuals worldwide (2). Around 400 PID genes have been identified to date (3, 4). It has 
been estimated that around 3,100 genes are involved in the connectome of cells within the 
immune system (5), suggesting that the genetic etiology of many PIDs have not identified to 
date. Most PIDs described until now are monogenic in origin but it is increasingly recognized 
that some of these diseases are polygenic in origin and may involve multiple cell types or 
organs. 
 
Some of the PIDs are life-threatening and diagnosed during childhood, resulting in serious 
symptoms, requiring a high level of care (e.g. gammaglobulin substitution, cytokine treatment 
and recently developed cellular and gene therapies (6)) and for the vast majority, no effective 
treatment presently exists. There are contraindications in the use of vaccines for PID patients, 
as significant vaccine-related adverse events may occur when live attenuated vaccines are given 
(7). Besides, severe PIDs such as severe combined immunodeficiency (SCID) requires early 
identification in order to initiate prompt treatment and improve survival (8). 
 
The identification of the causative gene in PID patients serves as the starting point for 
intervention which makes a more rapid and accurate diagnosis or test of pediatrics diseases and 
new therapeutic interventions possible. All of those effective precautionary tests, such as 
Premarital test, Antenatal test and Newborn Screening Test can not only promote the genetic 
testing progress of the PIDs and reduce the number of children with severe forms of 
immunodeficiency but also prevent transmission of hereditary diseases. 
 
1.2 NEXT GENERATION SEQUENCING TECHNOLOGY 
The rapid development of sequencing technologies in the past decade has dramatically 
changed the strategy and increased the pace of identification of causative genes of human 
diseases, especially the rare disorders (9). Considering the sequencing cost (10) and the 
technical effort involved, NGS is also rapidly becoming a routine for detecting SNVs and 
small InDels (11) (see Figure 1), which has resulted in a surge of discoveries on the cause of 
inherited diseases. Identification of pathogenic mutations and understanding of the 
underlying molecular mechanism serve as starting points for genetic diagnosis and 
counseling (12), while diseases such as familial forms of PID provides an opportunity to 
uncover mutations that may have implications both in PID and other immune-related diseases 
and may shed light on new therapeutic approaches for the disease. Over the past few years, 
researchers have investigated the etiology of many subtypes of PID on a molecular level and 
their clinical outcome by using Whole Exome Sequencing (WES) (13-18).  
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Figure 1. An exponential decay curve shows the cost of DNA sequencing has dropped dramatically (blue 
line), and the exponential growth curve shows sequenced human genomes number (red line) increased 
significantly over the past decade. 
 
Although WES focuses on the coding region of the genes which only constitutes 
approximately 1% of the whole genome, these regions are considered to contain 85% of the 
mutations underlying Mendelian disorders (19). Its use has dramatically increased research 
efficiency and has also significantly reduced the cost of research and the computation burden 
as well as save computer storage. Therefore, WES has been widely used for the causative 
gene identification of various types of inherited diseases (20-29). Several capture kits (Figure 
2) have been designed to capture all human exons, ranging from approximately 34 Mb to 71 
Mb in covered region size.  
 
The main limitation of WES after employing a sequence capture technology is the variability 
and noise due to capture and hybridization. Besides, WES is neither readily able to detect 
structural DNA changes (SVs) or copy number changes (CNVs), although these two kinds of 
variations cause a number of diseases, nor to detect variants located in the non-coding regions 
or coding regions where it is challenging to design the capture probes. Whole Genome 
Sequencing (WGS), which is more complete, thus tends to be increasingly attractive as an 
alternative for WES (30). Despite WGS being more reliable to detect all kinds of variation, 
SNVs, InDels, CNVs and SVs, our understanding of other genomic elements, such as in non-
coding regions, restricts the efficiency of annotation of pathogenic sequence variations (31). 
The Encyclopedia of DNA Elements (ENCODE) Project and Genotype-Tissue Expression 
(GTEx) Project (32-34) provide possibilities to accurately and completely annotate the 
various functional elements of the genome.  
 
Targeted region sequencing (TRS) is a more customized approach, which is a single test to 
evaluate many of the genes related to a particular disease. TRS has also been used to study 
diseases based on linkage analysis or homozygosity mapping. It usually uses a high depth 
sequencing result and has excellent performance in evaluating large genes (35) and detecting 
mosaic mutations. This method also allows an update of the panel regularly. 
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Figure 2. Covered region sizes (A) and gene number (including protein-coding genes, long/small non-
coding RNA genes, pseudogenes and Immunoglobulin/T-cell receptor gene segments) (B) of the capture 
target genes in different annotation databases for various exome enrichment designs.  
 
1.3 BIOINFORMATIC ANALYSIS  
Data analysis can be divided into two distinct parts: 1) Standard analysis which includes 
sequencing alignment and variant calling; 2) Advanced analysis which aims to determine the 
pathogenic variant.  
 
Burrows-Wheeler Aligner (BWA) (36) and the Short Oligonucleotide Alignment Program 
(SOAP) package SOAPaligner (SOAP2.21) (37) can be used to align reads onto the human 
reference genome (GRCh37/hg19 or GRCh38/hg38) and only mapped reads are kept for 
subsequent analysis. The calculation of coverage is based on all mapped reads in the target 
region. The fraction of target positions where we called a high-confidence consensus 
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genotype is comparable to the regions covered by probes in the capture kit. The consensus 
genotypes can be called by the Genome Analysis Toolkit (GATK) (38) or SOAPsnp (39).  
 
The genotypes different from the human genome reference were extracted as candidate 
variants, then the unreliable proportion was filtered out and finally obtained high-confidence 
variants for the investigated samples. These SNPs and InDels would be further annotated and 
categorized by an automated pipeline or annotation tools, such as Ensembl’s VEP (Variant 
Effect Predictor) (40), single nucleotide polymorphism effect (SnpEff) (41), ANNOVAR (42) 
and the Variant Annotation, Analysis and Search Tool (VAAST) suite’s Variant Annotation 
Tool (VAT) (43). Both canonical transcripts and the ones with the most severe consequence 
should be annotated to reduce the number of false negatives due to the incomplete annotation 
of transcripts (44). 
1.3.1 Candidate gene prioritization  
Artificial signals caused by various steps involved in the target region capture and sequencing 
process are generally thought of as noise. Neutral variants that were enriched in the 
sequencing platform, false positive variants due to low quality (quality score < 20 (Q20) or 
read depth < 4 folds) and variants with frequency >5% in geographical ancestry matched 
general population, were thus filtered out. The estimated copy number is no more than 2 and 
a distance between two SNPs shorter than 5 were also considered to be excluded in further 
analysis. 
 
Massive sequencing efforts such as the 1000 Genomes Project (KG), Exome Variant Server 
(ESP), Exome Aggregation Consortium (ExAC) and The Genome Aggregation Database 
(gnomAD) and data from large scale private sequencing projects provide a powerful 
foundation for candidate prioritization. An allele frequency higher than 1% in the normal 
population could be a reasonable threshold for filtering out polymorphisms for the most of 
rare diseases, pedigree and genetic inheritance should also be taken into account. 
 
The majority of variants cause disease by changing the sequence of amino acids which may 
further affect the function of the protein. Such amino-acids-sequencing-changing includes 
non-synonymous substitutions, donor and acceptor splice sites mutations, and 
insertions/deletions as well as truncation of proteins due to a premature stop codon. Thus, 
variants are prioritized based on the extent to which they can change the sequence of the 
protein product. 
 
A number of prediction software tools based on evolutionary conservation or protein structure 
have previously been developed, providing helpful information on the impact of variants. 
However, these tools should be used with caution since each of them has a certain percentage 
of false positives and false negatives. A uniform cutoff (the Mutation significance cutoff 
(MSC)) (45) is preferred in order to improve genome-wide accuracy. Genes that have a high 
gene damage index (GDI) (46) value are prone to enrich phenotype-irrelevant mutations as 
they are relatively less evolutionarily conserved, including sensory perception genes and long 
coding sequences. Besides, many false positive results come from these genes. 
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The mutations identified in the studied families represent all modes of Mendelian inheritance, 
autosomal dominant, recessive and X-linked. For many of the families, however, the exact 
mode of inheritance is unknown, especially for the families where only the proband is 
sequenced or the proband is the only affected case in the family. Therefore, different 
inheritance patterns should be considered to identify potential disease-causing variants 
(heterozygous for autosomal dominant, homozygous or compound heterozygous for 
autosomal recessive and hemizygous for X-linked), and identification of the causative gene 
in these cases would allow determining the inheritance pattern. 
 
Consanguineous families and families with multiple affected and unaffected individuals 
provide an advantage in disease gene identification by NGS. Since the former’s causal 
mutations are assumed to be inherited from a common ancestor, homozygosity mapping 
using the data from NGS will help to further narrow down the candidate genes to those within 
the homozygous regions. The latter will allow the evaluation of the co-segregation of 
candidate variants with the disease phenotype among family members. Thus, it is able to 
exclude all variants that do not show linkage to the disease. 
1.3.2 CNV detection  
The NGS field is evolving rapidly and novel cutting-edge methods are frequently made 
available for structural variant analysis (47-49), including paired-end mapping (PEM), read-
depth analysis, split-read strategies, and sequence assembly comparisons. By allowing the 
detection of point variants and inversion, NGS can estimate the exact location of a breakpoint 
since it is not based on hybridization, allowing a better estimation of high copy numbers (50). 
 
Nevertheless, CNV analysis based on WES data is still a challenge (51, 52). Abnormal GC 
content (53), PCR amplification bias and pre-existing InDels/CNVs (51, 52) can introduce 
bias. The latter causes bias of the sequence read quality score which needs to be re-calibrated 
for those known InDels in nearby regions. In addition, noise also exists due to the non-
uniform gene coverages, where longer genes and complex regions tend to have a better 
relative coverage. Statistical models have been introduced to solve this problem. Modeling 
the read-depth of each position, applying multiple algorithms (51) to estimate the noise (53) 
is a promising strategy to reduce false positives (54). Another option is to detect rare CNVs 
by using a complicated algorithm on WES data and infer using copy number polymorphic 
genotypes (55). However, each statistical model only serves a specific situation. 
 
In contrast to the extensively studied WGS workflow, identification of CNVs from exome 
data still can be erroneous when mistaking using packages or tools, even though some of 
them are customized for dealing with variabilities in WES studies. The usage of each 
tool/package can be case sensitive. By categorizing the existing algorithms using certain 
practical criteria, like reference dependent or independent, the way of setting the reference, 
the way of normalization, read-depth/split reads, etc., to get a better vision of the current 
status of existing algorithms, it is possible to add novel or complement ideas efficiently. 
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1.4 VARIANT INTERPRETATION AND CLASSIFICATION 
According to the joint consensus recommendation of variants interpretation suggested by the 
American College of Medical Genetics and Genomics (ACMG) (56), we found that most 
detected SNVs are classified as variants of unknown significance (VUS) which are private 
in many cases, and the more samples sequenced, the more VUSs are observed. To single out 
the pathogenic variants from the benign variants is critical for clinical pathogenicity. The 
recurrent observation of VUS after sequencing more samples and data sharing serves as an 
approach to knowing the potential consequence of VUSs. Functional assessment is another 
comprehensive approach but might be a labor-intensive way to analysis the molecular 
function of VUS. Site-directed mutagenesis and massively parallel functional assays had 
been used to distinguish pathogenic variants from polymorphisms in MSH2 (57) and BRAC1 
(58).  
 
In addition, penetrance is not considered in the existing classification system and it should 
be reported in the clinical screening reports. We learned that large-scale genome studies and 
experimental function can be informative for computational prediction development, and 
these results were also extremely useful for clinical practice, such as providing proper carrier 
counseling and allowing precision medicine. 
 
Although synonymous mutations are thought to be harmless as they do not alter the amino 
acid sequence are thus generally excluded in the further causative gene prioritization, 
synonymous mutations may alter protein expression, post-translational modification (PTM), 
stability and function. Rare codons reduce protein expression and affect rates up to various 
fold (59). Species-specific codon bias analysis might help to accurately interpret the 
consequence of gene variants and the effects of codon usage on gene expression, which would 
be beneficial to improve design principles for gene therapy. 
 
1.5 OLIGOGENIC ANALYSIS 
The above-described approaches have been most effectively utilized in familial and cohort 
studies for causative gene identification, mirroring the classic strategies of Mendelian disease 
studies. However, earlier findings suggest that a majority of patients with different forms of 
PID remain undiagnosed. In order to understand the underlying pathogenic mechanisms in 
undiagnosed patients, in particular in newly recognized polygenic forms of PID and diseases 
caused by a combination of heterozygous mutations in several PID associated genes, a 
broader and more comprehensive analytic approach might be necessary. 
 
The identification of the pathophysiological processes involved in polygenic forms of PID 
has been illuminated in recent years where combinations of heterozygous mutations in 
several PID associated genes have been recognized. More than one gene involved in a 
specific pathway (eg. the degranulation pathway, the IL7 signaling pathway and the DNA 
repair pathway) can contribute to a disease phenotype in a given family (60) or patients (61, 
62), where each of the variants may only explain a part of the phenotype (60, 61). Our 
previous work has suggested a potential ‘‘second-hit’’ mechanism (63) which also provides 
clues to the different phenotypes in family members although they carry the same causative 
variants. An increasing number of studies indicate that PID may be caused by 
6
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haploinsufficiency of genes, including CTLA4 (64, 65), NFAT5 (66), IKZF1 (67), GATA2 (68), 
SERPING1 (69), CHD7 (70), FAS (71), IFNGR2 (72), TNFRSF13B (73), NFKB1 (74) and 
NFKB2 (75). A combination of heterozygous mutations in two of them could result in an 
increased disease susceptibility that deserves special attention.  
 
Even so, since PID known genes and immunologically essential genes are spread throughout 
the genome, and NGS has unraveled a large number of rare variants. It is still a significant 
challenge to find a single variant in autosomal recessive traits genes that are compatible with 
the affected subject’s phenotype. In order to understand the underlying biological 
mechanisms in undiagnosed patients, in particular for polygenic forms of PID, the 
development of novel analytical approaches to filtering potential pathogenic variants and 
rapidly correlate them with patient phenotypes is in great need. 
 
1.6 VALIDATION AND REPLICATION 
Except for previously well-characterized variants and pathogenic variants in well-
characterized genes, validation is indispensable to eliminate false positive findings. First, 
these studies allow validation of the original variant in the studied pedigrees and geographical 
ancestry-matched healthy individuals, which is challenging by only using in silico analysis 
pipeline or predictor. Replication in additional samples provides convincing evidence for any 
novel causative genes. Confirmed data of genetic validation and segregation analyses from 
earlier studies show that all of these in silico methods have a 10-20% false negative and 10-
20% false positive rate. These methods provide an essential prerequisite but are not sufficient 
for determining whether a variant is pathogenic or disease-causing and should not be relied 
entirely on for identification. In vitro and in vivo studies can both be employed to explore the 
biological effect of a variant and no other method can replace a functional analysis for 
previously uncharacterized variants.  
 
Standard functional tests can be used to determine how causative genes are involved in 
immunity. These tests include molecular analyses (e.g., qPCR, microarrays, chromatin 
immunoprecipitation (ChIP) and RNA seq), biochemical analyses (e.g., western blot, 
electrophoretic mobility shift assay (EMSA), luciferase assays), gene transfer experiments, 
CRISPR/Cas9 knock-out/in trials and cellular studies. The cellular studies include 
immunophenotyping by flow cytometry (to test the appropriate CD markers), in vitro 
activation (Fascia) and differentiation tests, cytokine measurement by flow cytometry or 
multiplex enzyme-linked immunosorbent assay (ELISA). 
 
1.7 MULTIOMICS APPROACHES 
Despite tremendous advances in analyzing NGS data and efforts to create massive databases 
for mutations/variants, the observed mutations are often not possible to relate to the clinical 
phenotype. Moreover, a majority of patients with different forms of PID remain undiagnosed 
at the molecular genetic level. Given these difficulties, it is widely accepted that additional 
experimental methods, including epigenetics, transcriptomics, proteomics, metagenomics 
and determination of immune repertoires should also be employed in order to diagnose the 
patients.  
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1.7.1 Epigenetics 
Epigenetic factors, including DNA methylation, histone modifications and non-coding RNAs, 
play fundamental roles in cell development, differentiation and function (76, 77). It is well 
known that both during immune cell differentiation and B or T cell activation, DNA 
methylation combined with the transcription factors play a vital role in the regulation of gene 
expression (78), which through DNA methylation of cytosines in the context of cytosine-
guanine dinucleotides (CpG), often located in clusters (CpG islands) within regulatory 
regions such as promoters and enhancers. Epigenetics is also thought to be essential for V(D)J 
rearrangement, and immunological memory (79, 80) and recent studies have identified DNA 
methylation alterations in common variable immunodeficiency (CVID) (78), the 
Immunodeficiency, Centromere instability and Facial anomalies (ICF) (81, 82) and ATM 
deficiency (83).  
1.7.2 Transcriptomics 
The transcriptome is a direct link between genomic information and the proteome, and it is a 
starting point for studying the structure and function of a given gene. With transcriptome 
sequencing, variations in RNA sequence (SNPs and InDels), and downstream information 
including isoform expression, exon expression, gene structure refinement, alternative 
splicing, novel transcripts, and gene fusion can serve to complement the genomic sequencing. 
Transcriptomics can be directly interpreted to prioritize candidate disease-causing genes of 
Mendelian disorders, by detection of the aberrantly expressed genes, reveal mono-allelic 
expression and direct probing of splice isoforms to discover splicing defects. The aberrantly 
expressed genes can be due to the variants in the promoter, enhancer or intronic regions; these 
variants are tricky during the interpretation of genomics studies. It is also difficult to predict 
the consequence of splice site variant from the WES or WGS data by using current algorithms 
(84). Besides, we usually neglected the mono-allelic expression which due to heterozygous 
mutation of recessive genes, but it is essential for some specific patients. Transcriptome 
studies have proven to be a powerful strategy to the molecular diagnosis of 
mitochondriopathy patients (10% (5 of 48)) and to identify potential causative genes of the 
remaining patients (84). 
Comparative analysis of transcriptomic and methylome data will potentially be able to reveal 
changes in gene expression as a consequence of alterations in the methylation of relevant 
CpG sites. Further increase of the use of RNA sequencing may ultimately identify non-coding 
RNAs, alternatively spliced transcripts as well as allele-specific expression underlying 
immune dysfunction. 
1.7.3 Proteomics 
Proteome data represent the combined effect of the genetic, epigenetic, transcriptional and 
translational regulation and proteomics applications will thus provide valuable information 
about the "real-time" dynamic molecular phenotype (85). The quantitative proteomic analysis 
will be essential to understand underlying disease mechanisms which in turn will shed light 
on disease diagnosis, prevention, intervention, monitoring, and prediction of the treatment 
response (86). By acquiring both deep cellular and humoral proteome data, combined with 
available genomic data, incorporating sequence information on online proteomics database 
and analyzing the pathway activation status, it could be used to define PIDs associated 
8
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immune dysfunctions. It may thus be possible to understand the heterogeneity of the immune 
system and immune dynamics and has the potential to unravel diagnostic biomarkers. 
1.7.4 Metagenomics  
Over the past decades, emerging studies have suggested that the human gut microbiome plays 
a crucial role in the development of a range of diseases, including multiple sclerosis (87, 88), 
rheumatic diseases (89), amyotrophic lateral sclerosis (90) and atherosclerotic cardiovascular 
disease (91). Specific bacteria play a role in affecting or regulating the immune system (87, 
88). The composition changes of the gut microbiota have recently been observed in several 
forms of immunodeficiency in mice (92-94). Investigation of the population structure and 
taxonomic or functional features of the microbiota may unfold how gut bacteria regulate the 
immune system both in patients with PID and healthy individuals. 
1.7.5 Immune repertoires 
The diversity of antigen receptor repertoires is generated by recombination of the variable 
(V), diversity (D) and joining (J) gene segments, and is further augmented by junctional 
diversity (non-templated (N) nucleotide additions in the V-D and D-J junctions inserted by 
terminal deoxynucleotidyl transferase (TdT) and random deletion of nucleotides at the 
recombining edges as a consequence of asymmetric hairpin opening by ARTEMIS) (95-97). 
The productive T-cell receptor (TCR) repertoire further undergoes maturation in the thymus 
and through interaction with antigens.  
DNA double-strand breaks (DSBs) are cytotoxic lesions, which can be caused by pathogenic 
(ionizing radiation and radio-mimetic chemicals) or physiologic (introduced during V(D)J 
recombination and class switch recombination in developing lymphoid cells) conditions (98). 
Different forms of PID are associated with cancer and can develop due to genomic instability 
when DSBs are improperly repaired, such as in patients with Fanconi’s anemia, SCID, 
Ataxia-Telangiectasia (AT) and Nijmegen breakage syndrome (99). In addition, epigenetic 
modifications play a crucial role in the regulation of the active chromatin state in order to 
make the recombination signal sequences (RSSs) accessible to the recombinase (80), 
recruitment and stable binding of the recombination complex (100). The epigenetic plasticity 
involved in lymphocyte development and activation is a risk factor for human diseases 
associated with the immune system (100), such as in patients with mutations in DNMT3B 
(101-105) and ZBTB24 (106, 107) who develop ICF syndrome type 1 and type 2, 
respectively.  
It is now possible to analyze specific B or T cell antigen receptor (BCR or TCR) repertoires 
by using high-throughput sequencing technology and to characterize the repertoire clonality 
and investigate of the mechanisms of immune surveillance in PIDs in a single experiment. 
Immune repertoires as distinctive feature of antigen receptor (VDJ) rearrangement have been 
explored in a number of immunodeficiency diseases, including RAG deficiency (TCRβ and 
BCR) (108), ATM deficiency (TCRa and BCR) (109, 110), Cernunnos deficiency (TCRβ, 
TCRd and BCR) (96), Wiskott-Aldrich syndrome (TCRβ) (111) and CVID (TCRβ, BCR) 
(112, 113).	 The presence of immune repertoire diversity in patients with different 
immunodeficiency gene mutations provide opportunities to learn the effects of specific 
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causative genes which will deepen our understanding of the biology of these disorders and 
will provide insight into the clinical heterogeneity observed (97). 
1.7.6 Pathogen detection 
PIDs can lead to life-threatening infections, and therefore the timely and accurate microbial 
diagnostics is critical for implementing the individualized treatment plan. Current diagnoses 
include bacterial culture, qPCR and immunological essays, which are commonly used in 
clinical settings. However, these methods are either time-consuming or labor-intensive, and 
they can only detect a narrow range of pathogens in a single test. In contrast, NGS technology 
has compelling advantages over traditional methods. By unbiased sequencing nucleotide that 
extracted from the sample, NGS technology can comprehensively characterize underlining 
pathogens without prior knowledge. In addition, this approach can also detect some of the 
unculturable pathogens, rare pathogens and mixed infections, which often cannot be 
identified by traditional methods. Collectively, NGS technology enables rapidly and 
comprehensively microbial diagnostics of infection in PIDs patients and thus can accelerate 
the diagnostic process.  
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2 AIMS 
2.1 GENERAL AIM 
Using NGS technology to identify the genetic variations that are involved in the pathogenesis 
of PID and to investigate the immune repertoire characteristics and the monogenic and 
polygenic etiologies of PID, and to develop tools that can be used to facilitate the process of 
the genetic investigation. 
 
2.2 SPECIFIC AIMS 
2.2.1 We aimed to optimize the NGS bioinformatics analysis pipeline by integrating different 
analytical strategies, and to employ the pipeline in the investigations of the studied samples. 
2.2.2 To identify pathogenic variants in selected PIDs samples by using different NGS 
approaches. 
2.2.3 To improve the accuracy of molecular diagnosis and provide insights into genotype-
based care for patients with an atypical clinical presentation. 
2.2.4 To evaluate the feasibility and utility of the proposed sequencing approaches in the 
identification of genetic etiology of PIDs and beyond. 
2.2.5 To refine the prediction algorithms by using a Random Forest-based discriminator, 
which was established by utilizing the features of pathogenic variants and benign mutations 
and the integration of other existing prediction software. 
2.2.6 To characterize the T-cell receptor repertoire in selected PIDs patients, and to elucidate 
the role of different components of the DNA repair and methylation machinery in TCR 
repertoire profile and diverse phenotypes of immunodeficiency.	 	
11
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3 MATERIALS AND METHODS 
3.1 SUBJECTS 
Existing PID patient cohorts were collected at the Karolinska Hospital, the Children’s Medical 
Center (Pediatrics Center of Excellence affiliated to the Tehran University of Medical Sciences, 
Tehran, Iran) and outside collaborators. More than 600 samples have been subjected to NGS 
in the purpose of identifying underlying genetic causes. To exclude false-positive findings, 
healthy members of enrolled pedigrees were also collected for further co-segregation validation. 
Pre-test counseling was also carried out before genetic testing. The pre-test counseling includes 
a basic medical examination, medical history, family history, laboratory and molecular data, 
which are followed by a medical check-up for all participants. Informed consent was obtained 
from all patients or their legal guardians. Ethical permissions were obtained from the ethics 
committees of the participating centers. 
 
3.2 GENOMICS DATA GENERATION AND PREPROCESSING 
3.2.1 Whole exome sequencing (WES)  
To enrich exonic region of DNA, the Agilent SureSelect 50Mb exome capture kit (50Mb, 
Agilent Technologies, Santa Clara, CA) or the BGI exon capture kit for WES were used. 
Enriched DNA was loaded on Illumina (Illumina, San Diego, CA, USA) platform or the 
BGIseq500 platform (BGI, Shenzhen, China); 90 bases paired-end sequencing (Illumina) or 
100 bases paired-end sequencing (BGIseq) was performed for exon library sequencing.  
3.2.2 Targeted region sequencing (TRS) 
A custom capture kit was designed to capture 219 PID known genes (Table S1). TRS was used 
for hybridization, and the amplified library was sequenced on BGIseq500 platform with paired-
end 100 bp reads. 
3.2.3 Sequence alignment, variants calling and annotation 
The standard bioinformatics pipeline of WES/TRS data was performed as previously described 
(44). BWA, GATK and VEP were carried out for reads alignment to the GRCh37/hg19 human 
reference genome, variants calling and annotation, respectively. Public databases including KG, 
ESP, ExAC and gnomAD were used to identify and remove polymorphisms. CNVs were 
detected by ExomeDepth. 
3.2.4 Candidate prioritization 
A comprehensive pipeline for the annotation and clinical interpretation of the sequencing data 
relevant to PIDs was used to identify known and novel disease-causing variants in a high 
throughput fashion. The pipeline prioritizes variants for follow-up, relate them to existing 
clinical data, and provide a user-friendly interface for decision support. It was implemented a 
several-step process, which was described in our previously published paper (Figure 3) (44). 
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Figure 3. The diagram shows the pipeline of NGS-based disease gene identification in PIDs. The typical 
number of remaining variants after each prioritization step is indicated in the bar (44). 
3.2.5 Data mining 
In cases where the initial WES/TRS approach did not yield likely disease gene candidates, we 
considered the following options before proceeding to WGS. 1) relaxing the threshold criteria 
for statistical significance on the initial screening, followed by replication in additional cases, 
which has previously been employed successfully; 2) expanding the number of samples, if 
available, in order to increase the power for discovery and/or; 3) exploring the digenic or 
polygenic inheritance model for these undiagnosed patients (Figure 4).  
 
Figure 4. A framework shows the general consideration in PID cohort analysis. 
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3.2.6 Validation and replication 
The ACMG Standards and Guidelines (56) were used for evaluating all prioritized candidate 
variants. Only pathogenic variants, likely pathogenic variants or VUS were considered to have 
potential clinical relevance.  
 
If any of the above methods yielded disease gene candidates, we would attempt to validate 
them further to exclude sequencing errors. In addition, replicate relevant associations was also 
conducted by using additional samples. PCR amplification and Sanger sequencing were 
performed on the candidate variant. The absence of candidate variations in healthy members 
of the same family and normal individuals was required to exclude the possibility that the 
mutations are population specific non-disease-causing rare variation. Sanger sequencing of 
candidate genes in sporadic patients would also be performed to investigate the pathogenicity 
of candidate variations. 
 
3.3 PREDICTING PATHOGENICITY OF SINGLE NUCLEOTIDE VARIATIONS 
FOR PRIMARY IMMUNODEFICIENCY DISEASES 
3.3.1 Selection of training dataset for the prediction model 
Data on mutations with known pathogenicity leading to PID were collected from the 
Resource of Asian Primary Immunodeficiency Diseases (RAPID) database (114), which is 
one of the most comprehensive PID genomic variation databases. Mutations from the RAPID 
database were used as positive samples in the training dataset. To find negative samples of 
the training dataset, SNVs from the exome samples of gnomAD (115) were downloaded and 
annotated by VEP (40). The SNVs were used as negative samples in the training dataset only 
when the SNVs are not present in RAPID database and were reported as ‘benign’ or 
‘uncertain significance’ in the ClinVar database (116). Exome data from gnomAD was 
selected because it is the collection of mutation from 125,748 individuals, which contains a 
large number of rare mutations. This can reduce the risk of overestimating the performance 
of the model due to only using high-frequency mutations as negative samples in the training 
dataset.  
3.3.2 Annotation of the mutations 
To obtain the information of different features of SNVs, SNVBox (117) was used for 
annotation. The tool provided information about the properties of amino acid change, 
regional sequence composition, evolutionary conservation measurement, properties of SNV 
in 3D structural context and the functional impact on the translated proteins. All SNVs in the 
training dataset were also annotated by VarCards (118), an integrated annotation engine. 
Prediction scores from various genomic variation functional impact prediction tools were 
extracted and were used as features of SNVs in our VIPPID model.  
3.3.3 Machine learning and calculation of feature importance 
Data were processed by Perl version 5.22 and R version 3.4.4. R package ‘caret’ was used 
for Random Forest machine learning. To select features that contribute most to the accuracy 
of the model and to remove redundant features, R package ‘Boruta’ was used for feature 
selection. A score to indicate the importance of the feature was also calculated for each 
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feature. Function ‘tuneR’ in R package ‘randomForest’ was used for model tuning. The ‘mtry’ 
parameter was selected by choosing the one with the least Out-of-Bag error. An upper limit 
of 20 was set for ‘mtry’ to reduce the risk of overfitting. To evaluate the performance of the 
model, the model was trained and tested using non-overlapping datasets (cross-validation), 
in order to reduce the potential bias in the evaluation results, ten times cross-validation was 
performed. R package ‘pROC’ was used for ROC curve generation and AUC value 
calculation. 
 
In the gene-specific model, genes with 50 or more pathogenic SNVs were trained separately 
and each of these genes had an independent model. Genes with less than 50 SNVs were 
combined and trained in a common model. In the non-gene-specific model, all genes were 
trained in a common model, and mutations in all PID genes shared the same parameters in 
the model. 
 
Function ‘prcomp’ in R was used for principal component analysis. Package ggplot2 was 
used for data visualization. The median of feature importance values of each gene was 
calculated and used for principal component analysis (PCA), and feature importance value 
of -Inf was assigned as zero in the analysis. 
 
3.4 IMMUNE REPERTOIRE 
3.4.1 Sequencing of TCRb repertoires 
To amplify the CDR3 sequences of TCRb repertoires for equal amounts of DNA samples (1.2 
ug) from all TCR subjects, multiplex primers, and two complete sequencing adapter primers 
were adopted, as described in the previous work (95). We used AMPure XP (Beckman, A63882) 
to clean the first 15 cycles amplicons and purified PCR products were then amplified for a 
second round (25 cycles) with a pair of common primers. Prepared libraries were then loaded 
onto a BGIseq500 (BGI-Shenzhen, Shenzhen, China) and underwent 200 bp Single-end for 
sequencing. We obtained a mean of 5,971,100 (range 1,345,371 - 20,526,738) total reads and 
5,159,138 (range 824,569 - 17,542,667) clean reads for the sequenced samples.  
3.4.2 Bioinformatics analyses of TCRb repertoires 
IMonitor was used to analyze TCR sequencing data (69). After two rounds of the Basic Local 
Alignment Search Tool (BLAST), we obtained the final alignment result according to the 
optimal score (69). The International ImMunoGenneTics database (IMGT, www.imgt.org) was 
used as a reference. We performed in-frame and out-of-frame determination, V, D and J 
segments usage calculation, deletion/insertion nucleotide and amino acid sequence 
determination at the rearrangement with the default parameter, which has been illustrated in 
our previous work (69). We used “out-of-frame” to tag the rearrangement frame if the 
sequences with stop-codon or sequences with a length of non-multiple of three (frameshift); 
and “in-frame” were used as a tag under the alternative circumstance. Evenness is best 
expressed as a partial order, and this post structure can adequately be illustrated by Shannon-
Wiener's diversity (or entropy) index (H’) and the Gini evenness coefficient (G’) measured by 
considering three basic requirements: permutation invariance, scale invariance and the transfer 
principle. 
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3.4.3 Analysis of pathogen-associated sequences 
Totally, 20,814 pathology-associated CDR3 records of humans were collected from a manually 
curated database of T- and B-cell receptors targeting known antigens (TBAdb) 
(https://db.cngb.org/pird/tbadb/) and online databases McPAS-TCR 
(http://friedmanlab.weizmann.ac.il/McPAS-TCR/), where all records were derived by 
searching literature manually. All CDR3b sequences were used as a reference to perform 
alignment for all studied patients, identical sequences that were perfectly aligned to the 
reference were then calculated and annotated as specific for various pathogens. 
3.4.4 Statistical Analysis of immune repertoire 
R (R version 3.3.2) was used for statistical analysis and data visualization. We used normalized 
metrics from 1 million reads of data to describe the CDR3 sequences of each sample, including 
Shannon’s H index for measurement of repertoire diversity, Gini coefficiency of clonality, 
frequency of top 100 CDR3 clones, Pielou’s evenness index of V-J pairing, frequency of in-
frame and out-of-frame rearrangements, nucleotide composition of the CDR3 sequences and 
V gene usage. We investigated the differences of these metrics between groups and tested their 
statistical significance using a two-sided Wilcoxon Rank Sum Test.  
 
We used Bonferroni correction for multiple tests correction in V gene usage comparison. To 
investigate the patterns in each group during pre-selection and post-selection of TCRβ 
rearrangement, the length distribution of the CDR3 sequences and insertion/deletion sequences 
were further examined. For testing the distribution differences, two-sided bootstrap 
Kolmogorov-Smirnov test was used, and the significance of length difference between each 
group was tested by one-sided Wilcoxon Rank Sum Test. We performed PCA analysis and 
visualization by using the built-in R function and function from additional packages ggplot2 
downloaded from CRAN (https://cran.r-project.org/). Adjustments of all statistical tests were 
made to multiple testing corrections, p values ≤ 0.05 or the false discovery rate (FDR) ≤ 0.1 
were considered as significant. 
 
3.5 ETHICAL CONSIDERATIONS 
3.5.1 Risk Assessment 
Potential risks to the participants include medical and psychological concerns. The medical 
risks stem from blood drawing. Blood is preferable to saliva since the yield of DNA is much 
higher with blood than with alternatives. Besides, the presence of non-human DNA in saliva 
can complicate the analysis. Venipuncture may cause discomfort, bruising, or very rarely, 
infection. Only skilled medical assistants performed venipuncture and drawing the amount of 
blood which was only sufficient for this study. 
 
The psychological risks included: (1) distress when discussing a history of the disease and (2) 
loss of confidentiality. For the first concern, subjects were approached by doctors who were 
trained in counseling and discussing a family history of the disease. This set-up ensured that 
the participant was fully informed about the study before he/she made a decision about 
participation. Written consent was obtained from a proband, or in the case of children, both 
parents/guardians if the family was interested in participating. In terms of the concerns over 
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confidentiality, each participant was assigned an encrypted sample ID immediately upon 
recruitment to protect their privacy. Phenotypic information associated with their sample ID 
was kept in a separate secure locked file only accessible on a need-to-know basis. 
3.5.2 Potential Benefits 
Our findings may directly benefit the participants as it provides a correct diagnosis. 
Furthermore, data and conclusions derived from this study may push forward our 
understanding of the causes of PID and will ultimately lead to improved treatment options for 
patients, resulting in an enhanced quality of life. 
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4 RESULTS AND DISCUSSION 
4.1 COHORT SPECTRUM 
A total of 602 samples (including 88 healthy relatives) from 443 sporadic PID patients and 
57 multiple-case families with both affected and normal individuals spanning a broad range 
of PIDs have been collected. The symptom of patients represents pediatric and adult-onset 
disorders with a wide variety of phenotypes including CVID, Hypogammaglobulinemia, 
Agammaglobulinemia, Hyper IgM, combined immune deficiency (CID), SCID, IgA 
deficiency and other primary immunodeficiency categories according to 2017 IUIS 
phenotypic Classification for PID (4) (see Figure 5).  
 
 
Figure 5. The phenotype distribution of the studied patients (n=514), most of which were Common 
Variable Immunodeficiency. 
 
Among the 514 affected individuals, 98 of them (19%) were from consanguineous families. 
Most of the samples were from Iran (44%) and Sweden (31%), 69% of the patients were 
diagnosed as CVID (Figure 5). Four hundred and fifty samples (362 patients and 88 controls) 
were subjected to WES, whereas 217 samples (215 patients and two controls) were subjected 
to TRS, 65 samples (63 patients and two controls) went through both TRS and WES (Table 
1). 
 
Table 1. Number of pedigrees and samples with NGS performed. 
No. Pedigree Case Control 
WES 348 362 88 
TRS 216 215 2 
WES&TRS 64 63 2 
Total 500 514 88 
 
 
4.2 NONPATHOGENIC GENETIC VARIANTS 
There were in total 1,723,888 variants detected in the 450 samples that underwent WES, and 
14,322 variants called in the 217 samples that underwent TRS (Figure 6).  
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Figure 6. The distribution of consequences of the detected variants. 
 
Among the detected variants, we found that a notable proportion of them was frequently 
present in the patient cohorts but rare in public databases or in-house databases (Table 2). 
These variants are unlikely to be the pathogenic variants as most of the samples are unrelated 
and the clinical manifestation of patients is highly heterogeneous. Thus, the variants list was 
used to remove the artificial variants or nonpathogenic variants. 
 
Table 2. Statistics of genomic variants in mutation filtering. 
Filtering criteria Number of variants Percentage 
All variants 1,723,888 100.00% 
Rare in public databases (AF < 1%)* 1,165,663 67.62% 
Rare in in-house database (AF < 1%) 1,141,123 66.19% 
Common in PID WES cohort (AF > 1%) 130,199 7.55% 
Homozygous state in > 1% of samples 51,238 2.97% 
Common in PID WES cohort (AF > 5%) 48,655 2.82% 
Homozygous state in > 5% of samples 19,495 1.13% 
*AF: allele frequency 
     
4.3 MOLECULAR DIAGNOSIS 
4.3.1 Pedigree analysis 
Thus far, 514 patient samples from 500 pedigrees had undergone WES or TRS, 60% had 
received a likely molecular diagnosis (Figure 7). With the standard approach, we identified 
365 causal variants in 260 PID patients (50.6 %) who were submitted to TRS/WES. Copy 
number variation defect was identified in 16 patients (5.2%) who carries homozygous CNV 
(4 genes are involved, LRBA, ATM, DOCK8 and PMS2). A couple of known PID genes have 
been detected more than twice in different probands in our cohort. Analysis of NGS data 
revealed that ATM, LRBA, BTK, TNFRSF13B, DNMT3B, PRKDC, DOCK8, PIK3CD, 
CTLA4, IL12RB1, IL2RG, RAG1 and WAS are the most frequent causative genes, which in 
total explain the disease in approximately 33.6% patients (monogenic model) (Figure 7C 
and D). PID known genes (RAG1 (18), CD27 (17) and RAC2 (13)) with a new phenotype 
have been reported in several of our patients. In addition, two novel genes CD70 (15) and 
RAD50 were, for the first time, identified to be associated with primary immunodeficiency.  
 
 
WES TRS
Total Variants:14,322
A B
Total Variants:1,583,457
199,971 (11.6%)
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Figure 7. Inheritance pattern (A) and the spectrum of potential disease-associated variants (B) observed 
among 514 patients, and the treemaps show the frequency of the likely causative genes identified in the 
patients, either in a recessive (C) or dominant inheritance (D) model.  
4.3.2 Mutation frequency analysis 
We did not find any promising variants of in known PID genes for some samples, suggesting 
that there might be novel genes that contribute to immunodeficiency. As a large number of our 
patients were diagnosed as CVID, and we only found the disease-associated gene in a minority 
of them, we suspected that there might be some new, yet unidentified disease-associated genes 
among a subset of CVID patients.  
 
Conventional analysis strategy failed to find disease genes in those unsolved CVID samples, 
and we hypothesized that this might be due to variation in penetrance or expressivity, or 
heterogeneity of onset ages, which led to imperfect gene-phenotype co-segregations. For 
instance, disease-causative variant carriers could have no disease manifestation, which is 
mistakenly treated as healthy individuals, and those variants could be interpreted as benign 
since they presented in control samples. Thus, we employed a new method, which was to 
look for genes that had significantly higher mutation rate in unsolved samples than in others, 
to overcome the limitation. Since samples with similar phenotype have a higher possibility 
of sharing the same disease genes, we also further divided the 450 WES samples into four 
categories: CVID-unsolved, non-CVID-unsolved, non-CVID-solved and controls. Then we 
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looked for genes with likely pathogenic mutations in a significantly higher proportion of 
samples in the CVID-unsolved group as compared to the others (Fisher exact test) and 
selected them as candidate disease genes for further analysis. 
 
After applying the mutation frequency comparison strategy on the unsolved CVID and other 
groups, we identified 17 potential causal variants in 17 patients (5.5%). We found that the 
CVID-unsolved group has a higher proportion of individuals who carried rare deleterious 
mutations in multiple genes (TNFRSF18, PIK3CG, TXNIP, CD5, NLRP5 and EPHB2 for 
autosomal dominant mode; LILRB1 for autosomal recessive model) than the other groups 
(unpublished data).  
4.3.3 Digenic analysis 
The heterogeneity of the phenotype of patients from the same pedigree suggests that multiple 
genes might contribute to the disease. We used Fisher exact test to detect the statistical evidence 
of gene-gene interaction in patients, which was driven by the assumption that the proportion of 
cases carrying mutations in both of interacting genes is higher than expected in pairs of genes 
without interaction. This case-only approach combined with the phenotype-genotype 
correlations revealed the potential digenic inheritance model in our cohort. Remaining 
unsolved PID cases were submitted to the digenic inheritance model for further analysis, and 
this cohort-based approach suggested 32 possible causal mutations in 16 patients (5.2% in 
potential solved patients, 3.1% in all patients) who may follow a digenic inheritance model 
(unpublished data).  
4.3.4 The importance of early molecular diagnosis  
Among the patients who underwent TRS, a Swedish female patient who was diagnosed CVID 
at the age of 18. However, at that time, her condition was not a “typical” case of the disease, 
and thus no molecular diagnosis was made after the clinical diagnosis. It was not until 2017, 
when the patient revisited us for medical suggestions due to the progressive symptoms, 
including Lymphoma and Hemophagocytic Lymphohistiocytosis (HLH). A genetic 
investigation was launched soon thereafter. Unfortunately, at the time when the genetic result 
became available, which suggested ITK deficiency, the patient had already passed away due 
to her aggressive B cell lymphoma (119).  
 
We presented this case report in Paper III, which adds to the growing amount of evidence 
supporting the importance of genetic investigations initiated at an early stage of the patient´s 
disease. If the mutation in our patient had been known, she would have been referred for stem 
cell transplantation, which may have saved her life, instead of merely being given 
gammaglobulin substitution. In the conventional clinical setting, the clinical misclassification 
and inappropriate immunological phenotyping occur, which has hampered targeted therapy. 
Therefore, it is paramount to employ NGS as an initiatory procedure of the molecular 
diagnostic approach in dysgammaglobulinemia patients. Additionally, this tool could be used 
in aiding the therapy of patients and in genetic consulting for patients’ family members. 
 
In all, 117 genes and 430 variants have been identified by using a pedigree-based strategy and 
seven genes and 17 variants by a cohort-based approach. The total genetic diagnostic yield is 
60%, which is much higher than previously reported. A number of 204 patients remained 
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undiagnosed at the molecular level. These findings indicated that NGS genomic approach, 
together with large sample size and novel strategies, is powerful in decoding genetic 
characteristics of PID and provide insight into molecular mechanisms that cause the disease, 
and the utility of exome sequencing in the identification of novel genes underlying primary 
immunodeficiency. 
 
4.4 RANDOM FOREST-BASED VARIANT IMPACT PREDICTOR 
We also developed a Random Forest-based discriminator, VIPPID, to predict the impact of the 
gene mutation for the PID phenotype. We utilized 85 features scores from SNVBOX, combined 
with 24 impact scores from existing tools to train the model in either non-gene-specific model 
or gene-specific manner. A total of 1,664 pathogenic variants in 132 known PID genes obtained 
from RAPID database and 3,373 non-pathogenic mutations from gnomAD database were used 
as positive and negative samples in the training dataset, respectively. 
 
The non-gene specific model achieved an AUC value of 0.94, and the gene-specific model 
achieved a better accuracy with AUC of 0.95, showing considerable superior accuracy over all 
existing methods (Figure 8).  
 
Figure 8. Receiver operating characteristic curve (ROC) represent the predictions from VIPPID model 
and existing SNV effect prediction tools. Gene-specific VIPPID model (solid red line) and non-gene 
specific VIPPID model (solid blue line) have superior accuracy compared with existing prediction tools 
(non-solid lines). Numbers in parentheses indicate AUC value. 
 
Moreover, the machine learning algorithm can calculate an importance score for each feature 
of different genes, features with high importance scores were those that could best separate 
pathogenic mutations from non-pathogenic mutations, and they were also more likely to have 
a high impact on the function of the genes (Paper IV). 
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4.5 IMMUNE REPERTOIRE 
Repair of DNA double-strand breaks is important during antigen receptor recombination and 
creates a diversified repertoire for the developing lymphocytes. Mutations in multiple DNA 
repairing genes have a variable effect on adaptive immunity, resulting in a broad spectrum of 
immunological and clinical phenotypes. We investigated 19 patients with monogenic DNA 
repair defects and performed deep immune repertoire sequencing and bioinformatics analysis. 
Subsequently, patients were further categorized into 4 groups (atypical T+ SCID (n=3), AT 
(n=6), ICF1 (n=6) and ICF2 (n=4)) based on their molecular diagnosis and a comparison was 
made with 14 age-matched healthy controls to evaluate the roles of identified genetic defects 
during T cell receptor (TCR) recombination in Paper V. 
4.5.1 Restriction of TCR correlates with the pathogenic cause and the clinical 
phenotype  
Patients with different molecular diagnoses exhibited distinct repertoire diversity, clonality 
and V-J pairing patterns. Hypomorphic variants in a component of non-homologous end 
joining lead to atypical severe combined immunodeficiency affecting variable-joining (V-J) 
sections paring, and length and amino acids composition of complementarity-determining 
region 3 (CDR3). Patients with mutant ATM and ZBTB24 genes exhibited restriction of 
repertoire diversity, decreased clonality, skewed V-J pairing accompanied by aberrant CDR3 
length, whereas the patients with DNMT3B mutations presented longer CDR3 lengths and a 
lower percentage of out-of-frame rearrangements with a stop codon. Altered CDR3 length 
distribution was observed in unproductive and productive TCR in all patients, suggesting that 
it predominantly arises before thymic selection. Shorter CDR3 lengths in AT patients resulted 
from a decreased number of insertions, leading to an increase in the number of shared 
clonotypes, whereas patients with DNMT3B and ZBTB24 mutations presented longer CDR3 
lengths and reduced specificity for pathogen-associated CDR3 sequences. 
 
 
Figure 9. PCA plots illustrated the segregation of the AT and ICF2 patient groups from healthy controls 
on principal component 1 (PC1) and PC2 based on six variables (Pielou’s evenness (TCR), Gini skewing 
index (TCR), Gini skewing index (V-J paring), the percentage of in-frame rearrangement, mean CDR3 
length of out-of-frame rearrangement and the percentage of tyrosine in unique clones). 
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Principal components analysis (PCA) demonstrated the separation of AT patients, ICF2 
patients and healthy donors (green circles). It was based on six variables (Pielou’s evenness 
(TCR), Gini skewing index (TCR), Gini skewing index (V-J paring), the percentage of in-
frame rearrangement, mean CDR3 length of out-of-frame rearrangement and the percentage 
of tyrosines in unique clones) (Figure 9A). On the other hand, the ICF1 patients clustered 
together with the ICF2 group and the healthy individuals, the atypical SCID patients did not 
gather together in these characteristics, which may be due to the differences in causative 
genes. Neither the ICF1 group nor the atypical SCID patients could be differentiated from 
other groups (Figure 9).  
4.5.2 Discrepant enrichment of pathology associated T cells contributes to 
the phenotypic heterogeneity of immunodeficiencies 
Shorter CDR3 length in ATM-deficient patients resulted from significantly decreased 
nucleotide insertions, led to an increase in the pathology associated T cells clonotypes. The 
pathology associated TCRs showed a dramatically higher proportion of short CDR3 length 
compared to other unknown clonotypes, suggesting that pathology associated TCRs were 
preferentially shorter. 
 
The proportion of shared pathogen, autoimmunity and cancer-associated clonotypes was 
dramatically increased among the unique clones in the AT group. In contrast to AT patients, 
an extremely low frequency of shared pathogens specific clonotypes was recorded in the 
ICF1 patients, and a similar downward trend was also observed for the proportion of shared 
common clonotypes in both the ICF1 and ICF2 groups.  
 
Notably, a high frequency of pathogen-specific clonotypes was observed in the AT patients 
compared with healthy controls which might explain why opportunistic infections are rarely 
reported in AT patients. The rate of the total shared cancer specific clonotypes in our pediatric 
AT patients was reduced, perhaps reflected that none of the AT patients in this study had as 
yet developed cancer. 
 
 
In summary, the characteristics of the TCR repertoire observed in our study provided novel 
insights into the role of different components of the DNA repair/methylation machinery in TCR 
repertoire dysfunction and diverse phenotypes of immunodeficiency. Furthermore, for the first 
time, it shed light on to the mechanical etiology of T cell dysfunction in clinically similar 
diseases associated with DNMT3B and ZBTB24 deficiencies. 
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5 CONCLUSION AND FUTURE PERSPECTIVES 
 
WES/TRS and the bioinformatics used for this study had led to the discovery of the disease-
associated genes in over half of the families and cohorts, which was much higher than 
previously reported. In all, 430 variants in 117 genes were identified using a pedigree-based 
strategy, and 17 potential disease-causing variants in 7 genes were identified in a cohort-based 
approach in the patients we studied. Around 200 patients remain undiagnosed at the molecular 
level. 
 
For the majority of the remaining “unsolved” patients, there were several factors which could 
have contributed to such an undiagnosed situation. 1) TRS and WES are not able to capture 
variants located in non-coding regions which could have resulted in the phenotypes (120); 2) 
Structure variations that contribute to PID (121) failed to be identified by adopting the existing 
library construction and data analysis method which was based on gene panels; 3) Pre-existing 
and complex PID genotype-phenotype relations may confuse our analysis of the heterozygous 
mutations in a number of known genes that previously reported as under a recessive model or 
related to haploinsufficiency. 4) Variation in penetrance or existence of modifying genes in PID 
patients led to the failure of co-segregation and thus impeded the identification of the genetic 
cause (122-124). 5) Furthermore, the limitation of existing mutation pathogenicity prediction 
tools might also lead to some false negatives in disease mutation identification. The new 
Random Forest based model we developed was a proof of concept of using gene-specific and 
disease-specific model can improve the accuracy of pathogenicity prediction for variants in the 
PID genes. 
 
We should learn from Paper II and Paper III that early and appropriate molecular diagnosis 
is of utmost need, and genetic testing is strongly advocated for all CVID patients associated 
with HLH for taking prompt action and adjust treatment to improve survival. Thus, we will 
employ a variety of methods on our undiagnosed patients and try to make a molecular diagnosis. 
 
WGS will be used to detect large insertions or deletions, copy number variations or structural 
variations, which are not easily traceable using WES. Meanwhile, increasing the sample size 
and integrating rare nonpathogenic genetic variants found in public or private databases, 
especially for the ethnically diverse populations (125, 126), this is capable of improving the 
analytical power for the novel genes or gene-gene interaction identification.  
 
Other factors may also contribute to the development of the disease, for instance, alterations in 
the epigenome, transcriptome, proteome or microbiome can influence the disease phenotype 
(127), and we will, therefore, consider using alternative strategies to look for other explanations 
for the disorders in our patients.  
 
Inspired by the recent findings suggesting that cardiovascular-disease-related protein 
alteration can be driven by genetics and the gut flora (128), we would like to explore the 
potential interrelationship and the joint effects between the genetics and the microbiome in 
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IgA deficiency, in the hope of providing new therapeutic paradigms for future applications in 
personalized medicine. Moreover, given that PID is especially susceptible to be infected by 
the pathogen, integrating other multi-omics studies could help us to establish a 
comprehensive understanding about PID, which can be useful in guiding individualized 
treatment in the clinical setting.  
 
Some new technologies could also be helpful for disease screening or diagnosis, for instance, 
recently developed single tube long fragment read (stLFR) (129), provide possibilities of 
non-invasive prenatal testing of PIDs by sequencing the maternal plasma DNA. T-cell 
receptor excision circles (TRECs) and κ-deleting recombination excision circles (KRECs) 
assay combined with conventional genome sequencing may also enable a direct identification 
of the genetic cause of PIDs, and this will allow a more rapid and accurate diagnosis and 
provide clues for therapeutic interventions. 
 
In summary, the application of NGS and other new technologies, along with innovation in 
research strategies, will facilitate the identification of more disease genes. Integrated 
knowledge of PID genes or mutations and phenotypes will be helpful to elucidate the genetic 
causes of the diseases and to simplify the procedure of the genetic diagnostic setting while 
improving the diagnostic yield. 
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